Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Carmine Therapeutics

Request full access

Developing novel types of gene therapies that utilize extracellular vesicles (EVs) produced in the laboratory

Cambridge, United StatesFounded 2019Biotech & Life Sciences

About Carmine Therapeutics

Carmine Therapeutics, headquartered in Cambridge, Massachusetts, is an innovative biotech company specializing in the development of next-generation gene therapies. The company leverages a unique technology based on red blood cell extracellular vesicles (RBCEVs). These vesicles are naturally produced by red blood cells and are devoid of genetic material, making them biocompatible and non-immunogenic, meaning they do not provoke an immune response. This is a significant advantage over traditional viral-based gene therapies, which often face challenges such as immune reactions, limited capacity for genetic material, and complex manufacturing processes.

Carmine Therapeutics' proprietary Red Cell EV Gene Therapy platform allows for the creation of a wide range of disease-modifying gene therapies. These therapies are designed to treat a broad spectrum of diseases by utilizing the modular nature of RBCEVs. The vesicles can be easily manipulated to load nucleic acids and modify their surfaces, making them highly adaptable for various therapeutic applications.

The company's business model focuses on research and development (R&D) to create these advanced gene therapies. Carmine Therapeutics collaborates with other biotech firms and pharmaceutical companies, such as Takeda, to co-develop and commercialize these therapies. Revenue is generated through partnerships, licensing agreements, and potentially through the direct sale of their proprietary therapies once they receive regulatory approval.

Carmine Therapeutics primarily serves clients in the healthcare and pharmaceutical sectors, including patients suffering from genetic disorders, healthcare providers, and other biotech companies looking for innovative gene therapy solutions. The market it operates in is the rapidly growing field of gene therapy, which aims to treat or prevent diseases by modifying the genetic material within a patient's cells.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
None listed
Dealroom signal
58.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2022 $14M $55M Cystic Fibrosis Foundation · Evx Ventures · Huagai Capital · Simcere Pharma ↗
SUPPORT PROGRAM✓Other financing Nov 2021 $0 — Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Carmine Therapeutics website traffic

Latest recorded traffic for Carmine Therapeutics is 2.2K monthly website visits, up 129.2% over the last three months. Carmine Therapeutics's team grew 0% over the past year.

Latest monthly visits2.2K 3-month web change+129.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Carmine Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Carmine Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Esco Ventures
  • Takeda
  • EVX Ventures

Series A3 investors entered at this stage

  • Huagai Capital
  • Cystic Fibrosis Foundation
  • Simcere Pharma

Other known investors3 additional known investors

  • City University of Hong Kong
  • National University of Singapore
  • Falling Walls Foundation
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇸🇬 Singapore50%
🇨🇦 Canada25%
🇸🇦 Saudi Arabia25%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Carmine Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Carmine Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.